上海醫藥(02607.HK)一季度淨利升104.24%至21.20億元
格隆匯 4 月 28日丨上海醫藥(02607.HK)公佈,2021年第一季度,雖有集採擴面等行業政策壓力,但依託於一體化發展的產業鏈、豐富的產品資源、廣闊的銷售渠道、多元的創新模式、優秀全面的服務,公司各項業務蓬勃發展,取得的業績成果相較於去年同期十分亮眼。
報吿期內,公司實現營業收入516.00億元(人民幣,下同),同比增長27.57%;其中醫藥工業實現收入64.66億元,同比增長14.43%;醫藥商業實現收入451.34億元,同比增長29.70%。
報吿期內,公司實現歸屬於上市公司股東的淨利潤21.20億元,同比增長104.24%,主要來自上藥雲健康B輪融資後出表形成的一次性收益;實現扣除非經常性損益的歸屬於上市公司股東淨利潤12.13億元,同比增長23.39%;其中醫藥工業主營業務貢獻利潤5.53億元,同比增長6.77%;醫藥商業主營業務貢獻利潤5.86億元,同比增長26.69%;參股企業貢獻利潤3.22億元,同比增長20.66%。
報吿期內,公司持續加大研發投入,金額達5.41億元,同比增長56.25%,其中研發費用投入4.15億元,同比增長21.47%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.